SLURP; A phase 2 intervention study: Detection of early esophageal neoplastic lesions by quantified fluorescence molecular endoscopy using oral and topical administration of bevacizumab-800CW and cetuximab-800CW

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503801-12-00

Acronym

16054

Enrollment

Registered

2023-05-22

Start date

2023-09-15

Completion date

Unknown

Last updated

2024-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Barrett's esophagus

Brief summary

Feasibility and safety of oral tracer administration, Evaluate combined tracer administration lead for increased lesion detection

Detailed description

Safety data on oral (combined) tracer administration, Quantify in vivo fluorescent signal and compare to ex vivo expression of VEGFA/EGFR, Specify and objectify the improvement of qFME and tracer administration

Interventions

DRUGAvastin 25 mg/ml concentrate for solution for infusion

DRUGErbitux 5 mg/mL solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Safety data on oral (combined) tracer administration, Quantify in vivo fluorescent signal and compare to ex vivo expression of VEGFA/EGFR, Specify and objectify the improvement of qFME and tracer administration	—

Primary

Measure	Time frame
Feasibility and safety of oral tracer administration, Evaluate combined tracer administration lead for increased lesion detection	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026